Stanford Cancer Institute

Cancer Cell Therapy

CAR-T Therapies for Aggressive Large Cell Lymphoma Age ≥ 18 Yrs

- CAR Therapies following prior CAR Therapy
- Expanded Access protocols for commercial CAR-T products manufactured of specification
- 3rd line CAR Therapies
  - Age < 65 Yrs
  - Age > 65 Yrs

CCT5029
Phase I/II
Autologous
CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Pt: Muffy Stanford

CCT5024
Phase I/II
ALLO-501 (AntiCD19 Allogene CAR TCell Tx) Relapsed/Refractory Large B-Cell & Follicular Lymphoma
Pt: Miklos Allogene

CCT5035
Phase I/II
PB CAR20A B Relapsed/Refractory (B/R) NHL or R/R CLL or Small Lymphocytic Lymphoma
Pt: Miklos Allogene

CCT5051
Phase I
ADI-001 Anti-CD20 CAR-Engineered Allogeneic GammaDelta T Cells +/- IL-2 in BCell Malignancies
Pt: Miklos Sponsor: Adicet Bio, Inc.

CCT5006
Expanded Access
Axicabtagene Ciloleucel in Tx Relapsed/Refractory T-plant-correlatable Aggressive NHL
Pt: Miklos Sponsor: Kite

CCT5016
Managed Access Program (MAP) CTL019 in ALL or DLBCL
Pt: Miklos Sponsor: Novartis

CCT5034
Expanded Access
KTE-X19 in Relapsed/Refractory B-Cell Malignancies
Pt: Miklos Sponsor: Novartis

CCT5045
EAP for Patients Receiving Axicabtagene Maraleucel That is Non-conforming for Commercial Release
Pt: Miklos Sponsor: Juno Therapeutics, Inc.

CCT5044
Phase II trial of Bi-specific scCD19 & α-20 CD28 CAR-T
Pt: Miklos Sponsor: Pending

CCT5036
Phase II
Linzilumab &Axicabtagene Ciloleucel in Relapsed/Refractory Large B-cell Lymphoma
Pt: Parveen Sponsor: Kite Pharma

CCT5032
Phase II
Anti-CD30 & Anti-CD19 Specific Chimeric Antigen Receptor in Relapsed and/or Refractory DLBCL
Pt: Miklos Sponsor: Stanford

CCT5042
Pilot
18F-F-AraC PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
Pt: Miklos Sponsor: Stanford

KEY
- Pending
- Open for Enrollment
- Optional Path
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu